Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosyltransferase 5 (ART5)
- Target
- ART5
- Molecular classification
- Enzyme, ADP-ribosyltransferase, Mono(ADP-ribosyl)transferase, Secreted protein
01
Overview
ADP-ribosyltransferase 5 (ART5) is a member of the arginine-specific ADP-ribosyltransferase family, catalyzing the transfer of ADP-ribose from NAD+ onto arginine residues in target proteins, thereby regulating their function. Unlike membrane-anchored family members ART1 and ART2, ART5 is secreted and exhibits unique catalytic properties, such as dual catalytic activity dependent on NAD+ concentration and auto-regulatory modification through auto-ADP-ribosylation. These features contribute to ART5’s distinct biology and tissue specificity. ART5 has been implicated in cell signaling and protein regulation and has emerging relevance as a biomarker in cancer research.
- Other names
- ART5ARTC5Ecto-ADP-ribosyltransferase 5Mono(ADP-ribosyl)transferase 5NAD(P)(+)--arginine ADP-ribosyltransferase 5ADP-ribosyltransferase C2 and C3 toxin-like 5
02
Mechanism of action
Enzyme inhibition by analogs of NAD+ or arginine; Regulation through auto-ADP-ribosylation
03
Biological functions
Protein ADP-ribosylation (post-translational modification)Regulation of protein functionCell signalingPossible involvement in cell communication
04
Disease associations
Cancer (reported in colorectal cancer gene signatures and in processes related to castration-resistant prostate cancer)Other (potential biomarker in disease)
05
Safety considerations
None specifically reported in public sources for ART5. General challenges of enzyme inhibition include off-target effects and disruption of NAD+-dependent processes.
06
Interacting drugs
No approved drugs directly targeting ART5 are known. Small molecule arginine analogs (e.g. agmatine, meta-iodobenzylguanidine) can inhibit ADP-ribosylation, but these are not specific clinical drugs for ART5
07
Biomarkers
Transcript levels of ART5 have been included in prognostic gene signatures for colorectal cancer
Beyond the preview
Go deeper on ADP-ribosyltransferase 5 (ART5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADP-ribosyltransferase 5 (ART5).